Clinical features of patients with anti-CCP antibodies
| Sex, age (y) | Dis dur | Anti-CCP (U/ml) | Anti-pepA or pepB reactivity | RF (titre) | SJC | RXJC | Asym oligo dis | Features helpful in distinguishing PsA from RA | Family history | DMARD* | Psoriasis subtype | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| *Current treatment in bold. | |||||||||||||||||||||
| asym oligo dis, asymmetrical oligoarticular disease (No(1), polyarticular disease; No(2), symmetrical oligoarticular disease); CCP, cyclic citrullinated peptide; CS, corticosteroids; CyA, ciclosporine; DIP, distal interphalangeal joint; Dis dur, disease duration; Dpen, D-penicillamine; IBD, inflammatory bowel disease; MTX, methotrexate; NA, no radiographs available; PsA, psoriatic arthritis; RA, rheumatoid arthritis; RF, rheumatoid factor; RXJC, radiological erosive or destructive joint count; SASP, salazopyrine; SJC, number of swollen joints; y, years. | |||||||||||||||||||||
| F, 39 | 15 | 54 | PepA+PepB | 160 | 6 | 19 | No(1) | Enthesitis, dactylitis, inflammatory low back pain, DIP involvement. | Infliximab + MTX + SASP | Nail involvement | |||||||||||
| M, 24 | 5 | 54 | Neg | 320 | 10 | 17 | No(1) | DIP involvement | Psoriasis, IBD | CyA+CS + MTX +Dpen | Nail involvement | ||||||||||
| M, 60 | 5 | 72 | PepA+PepB | 1280 | 4 | 3 | No(1) | MTX | Vulgaris | ||||||||||||
| M, 68 | 17 | 93 | Neg | 640 | 10 | 34 | No(1) | DIP involvement, enthesitis, dactylitis, sacroiliitis, ankylosis | MTX+CS | Vulgaris and nail involvement | |||||||||||
| M, 67 | 20 | 353 | PepA | 2560 | 2 | 38 | No(1) | DIP involvement, enthesitis, dactylitis | MTX+CS | Vulgaris and nail involvement | |||||||||||
| F, 50 | 5 | 500 | PepA+PepB | 80 | 0 | NA | No(1) | Enthesitis, dactylitis, sacroiliitis, inflammatory low back pain | Psoriasis | Infliximab+MTX | Vulgaris | ||||||||||
| M, 37 | 6 | 1100 | PepA+PepB | 160 | 6 | 1 | No(1) | Psoriasis, PsA | MTX+SASP | Vulgaris and nail involvement | |||||||||||
| F, 54 | 11 | 1113 | PepA+PepB | 80 | 0 | 1 | No(1) | Psoriasis | MTX+SASP | Nail involvement | |||||||||||
| F, 68 | 6 | 1375 | PepA+PepB | 160 | 4 | 0 | No(1) | Psoriasis | Infliximab +MTX | Vulgaris | |||||||||||
| F, 48 | 9 | 1456 | Pep B | 320 | 2 | 14 | No(1) | Ankylosis | Etanercept +CyA+MTX | Vulgaris | |||||||||||
| F, 31 | 1 | >1600 | PepA+PepB | 640 | 5 | 0 | No(1) | Enthesitis | SASP | Vulgaris and nail involvement | |||||||||||
| F, 51 | 8 | >1600 | PepA+PepB | 1280 | 1 | 0 | No(1) | Dactylitis, enthesitis | Psoriasis | Absent | Vulgaris and nail involvement | ||||||||||
| M, 46 | 1 | >1600 | PepA+PepB | 320 | 0 | 0 | Yes | Enthesitis | Psoriasis | SASP | Vulgaris and nail involvement | ||||||||||
| M, 63 | 5 | >1600 | PepA+PepB | 1280 | 9 | 7 | No(1) | DIP involvement, enthesitis, dactylitis | MTX | Vulgaris | |||||||||||
| M, 69 | 6 | >1600 | PepA+PepB | 160 | 0 | NA | No(2) | MTX+gold | Vulgaris | ||||||||||||